

## Laboratory Service Report

1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
REPORTVALIDATION, AUTOMATION D	RVDMOHB022	40	F	RVDMOHB022
Ordering Phys		DOB		
		01/01/19	71	
Client Order #	Account Information			Report Notes
RVDMOHB022				
Collected	C7028846-DLMP ROCHESTER			
09/01/2011 08:40	3050 SUPERIOR DRIVE			
Printed	ROCHESTER,MN 55901			
09/02/2011 06:59				

Test	Flag	Results	Unit		Referen Value	ce Perform Site*
BCR/ABL Mutation, ASPE Specimen Type BCRABL Fusion Form Final Diagnosis: Peripheral blood, BCR/ABL K:	inase Domain	Peripheral blood p210 Mutation Analysis:	REPORTED	09/01/	2011 11:	31 MCR MCR MCR
Positive. Two mutations we domain region. The dominant corresponding amino acid cha mutations with corresponding These mutations have individ clinically significant resis (O'Hare T, et al. Blood 200' significance of finding more patient is not clear.	ere detected t mutation w ange is T3 g amino acid dually been stance to im 7; 110:2242- e than one m	in the ABL kinase with its B151. Additional sinclude: E355G. associated with hiatinib therapy -2249). The mutation in a given				
Per provided client informat to have a p210 BCR-ABL mRNA	tion, this p transcript	patient is reported type.				
Signing Pathologist: Carey This assay detects approxima described and most frequent mutations, which have been a clinical or in vitro resista inhibitor therapy (M351T, T M244V, E355G, G250E, F317L, Additional mutations of pote are not covered by this test cannot be excluded.	Lueck ately 80% of ly occurring associated w ance to tyrc 315I, E255K, Y253H, Y253 ential or un t methodolgy	the currently ABL kinase domain with significant sine kinase H396R, F359V, F, and Q252H). known significance and therefore				
Method Summary: Total RNA of transcription PCR was perfor transcript and ABL kinase do domain mutations (KDM) were multiplex allele-specific ex analyzed for specific mutat: platform (see Mayo Medical D Handbook for method details Laboratory developed test.	was extracter rmed to deter omain (KD) r evaluated u xtension (AS ions using 1 Laboratories ).	ed and nested reverse act the BCR/ABL region. Kinase using a fluorescent SPE) assay and Liquid bead array s Interpretive				

\* Performing Site:

	MCR	Mayo Clinic Dpt of Lab Med & Pathology 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.
--	-----	---	--

Patient Name	<b>Collection Date and Time</b>	Report Status
REPORTVALIDATION, AUTOMATION D	09/01/2011 08:40	Final
Page 1 of 1		** End of Report **

\* Report times for Mayo performed tests are CST/CDT